QR056251

QR056251 is a small molecule drug candidate being developed by Createrna Development for the treatment of idiopathic pulmonary fibrosis (IPF). It acts as an inhibitor of Rho-associated protein kinase (ROCK), an enzyme that plays a pivotal role in regulating the actin cytoskeleton and mediating various cellular functions such as contraction, migration, and proliferation. In fibrotic diseases like IPF, ROCK signaling is upregulated, contributing to the activation of myofibroblasts and the excessive accumulation of extracellular matrix in the lungs. By targeting this pathway, QR056251 aims to reduce fibrotic progression and preserve lung function. The compound is currently in the IND-enabling phase, with preclinical studies supporting its transition into clinical development.